Unknown

Dataset Information

0

Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.

ABSTRACT: Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells in vitro and in vivo, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.

SUBMITTER: Shi X 

PROVIDER: S-EPMC4894437 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.

Shi Xianping X   Lan Xiaoying X   Chen Xin X   Zhao Chong C   Li Xiaofen X   Liu Shouting S   Huang Hongbiao H   Liu Ningning N   Zang Dan D   Liao Yuning Y   Zhang Peiquan P   Wang Xuejun X   Liu Jinbao J  

Scientific reports 20150408

Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and  ...[more]

Similar Datasets

Unknown Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
| S-EPMC3938960 | biostudies-literature
Unknown The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
| S-EPMC8423655 | biostudies-literature
Unknown Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
| S-EPMC8776734 | biostudies-literature
Unknown Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells.
| S-EPMC8959513 | biostudies-literature
Unknown Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
| S-EPMC6836452 | biostudies-literature
Unknown Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.
| S-EPMC8125500 | biostudies-literature
Unknown A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis.
| S-EPMC6822579 | biostudies-literature
Unknown Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
| S-EPMC8222327 | biostudies-literature
Unknown EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells.
| S-EPMC7797660 | biostudies-literature
Unknown BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis
| S-BSST1072 | biostudies-other